Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
Zander T, Pabst T, Schär S, Aebi S, Mey U, Novak U, Lerch E, Rhyner Agocs G, Goede J, Maniecka Z, Hayoz S, Rüfer A, Renner C, Driessen C. Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial. Leukemia 2023; 37:699-701.
12.01.2023
Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
12.01.2023
Leukemia 2023; 37:699-701
Zander Thilo, Pabst Thomas, Schär Sämi, Aebi Stefan, Mey Ulrich J M, Novak Urban, Lerch Erika, Rhyner Agocs Gaëlle, Goede Jeroen, Maniecka Zuzanna, Hayoz Stefanie, Rüfer Axel, Renner Christoph, Driessen Christoph
Weiter